Barclays Forecasts Strong Price Appreciation for Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health (NASDAQ:PAHC) had its price target increased by equities researchers at Barclays from $13.00 to $20.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s target price indicates a potential downside of 21.63% from the company’s previous close.

PAHC has been the topic of a number of other research reports. JPMorgan Chase & Co. assumed coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price on the stock. Bank of America upped their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $16.50.

Phibro Animal Health Price Performance

Phibro Animal Health stock traded down $0.03 during trading hours on Tuesday, reaching $25.52. 74,906 shares of the stock were exchanged, compared to its average volume of 156,104. The stock has a 50 day moving average of $22.46 and a two-hundred day moving average of $19.52. The company has a market cap of $1.03 billion, a P/E ratio of 59.54, a price-to-earnings-growth ratio of 0.58 and a beta of 0.51. The company has a current ratio of 3.23, a quick ratio of 1.64 and a debt-to-equity ratio of 1.81. Phibro Animal Health has a twelve month low of $9.40 and a twelve month high of $25.92.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The business had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. Equities analysts expect that Phibro Animal Health will post 1.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director E Thomas Corcoran bought 5,000 shares of Phibro Animal Health stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the acquisition, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 50.07% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. grew its stake in Phibro Animal Health by 56.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock worth $1,030,000 after purchasing an additional 28,584 shares during the period. Illinois Municipal Retirement Fund boosted its holdings in shares of Phibro Animal Health by 7.2% during the 1st quarter. Illinois Municipal Retirement Fund now owns 11,430 shares of the company’s stock worth $148,000 after buying an additional 765 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Phibro Animal Health by 32.8% during the 1st quarter. Acadian Asset Management LLC now owns 675,207 shares of the company’s stock worth $8,726,000 after buying an additional 166,776 shares in the last quarter. Sofinnova Investments Inc. acquired a new stake in shares of Phibro Animal Health during the 2nd quarter worth approximately $3,975,000. Finally, nVerses Capital LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at $70,000. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.